ADAlexandra Oltea Dan

Alexandra Oltea Dan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alexandra Oltea Dan has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Molecular Targeting of the Peripheral Nerve–Tumor Axis in Extracranial Solid Cancers: Eight Signaling Systems, One Effect—Systematic Review and Multilevel Meta-Analysis

    by Diana-Rodica TudorașCu, Cristin Constantin Vere, Mihai Petrescu, Ana-Maria Ciurea, Răzvan-Cosmin Pană, Alexandra Oltea Dan, Elena-Anca Târtea, Andrei GreșIță, Diana-Ruxandra Hădăreanu, Cosmin Vasile Obleagă, et al.

    The peripheral nerves that innervate solid tumors communicate with the malignant cells through a restricted set of molecular signaling systems: adrenergic and muscarinic receptors, sensory neuropeptides, neurotrophins and their tyrosine kinase receptors, axon guidance molecules, and nociceptor ion channels. Each has been proposed separately as a therapeutic target but never quantitatively compared with the others. The question is whether one of them dominates—or whether the real target is the axis as a system. We systematically searched PubMed, Scopus, and Web of Science, with four query modules per database, without year or language restriction. We included in vivo studies in mammals, on extracranial solid cancers, with an intervention that modulated tumor innervation, peripheral nerve activity, or neural signaling, and with at least one tumor burden outcome. Of 16,649 unique records, 362 were included, with 1291 experiments and 1437 effects. Blockade of the peripheral nerve–tumor axis reduced tumor burden by −44.8%. In the prespecified primary analysis, on established tumors, the reduction was −52.0% with no significant difference from preventive interventions (p = 0.17). All eight molecular signaling systems responded to blockade, with estimates ranging from −34.3% for TRP channels to −70.2% for glutamatergic signaling. Interventions that activate the axis produced the opposite effect, with a 52.1% increase (95% CI: 32.1 to 75.1) across 253 effects, and bidirectionality was demonstrated within the same molecular system for the adrenergic compartment (−42.8% for blockade vs. 58.1% for activation), axon guidance molecules, and TRP channels. Egger’s test indicated marked small-study effects (slope −1.12; p < 0.001); the estimate remained stable when low-confidence digitized values were excluded (−42.6%). Eight distinct molecular signaling systems, disrupted by methods with nothing in common, produce reductions of a similar magnitude in tumor burden, and stimulation of three of them produces the opposite effect.

  • Open Access

    PAI-1, MTHFR, and FVL Thrombophilic Polymorphisms as Risk Factors for Fetal Growth Restriction: A Case–Control Study from a Tertiary Care Center

    by Răzvan-Cosmin Pană, Nicoleta-Loredana Anghel-Savciu, Marina Dinu, Dan Ruican, Ana-Maria Petrescu, Alexandra Oltea Dan, Elena-Anca Târtea, Andrei GreșIță, Diana-Ruxandra Hădăreanu, Diana-Rodica TudorașCu, et al.

    Background/Objectives: Fetal growth restriction (FGR) is one of the main causes of perinatal morbidity and mortality, and in most cases the mechanism is placental dysfunction of vascular origin. Hereditary thrombophilias have been evaluated as factors that favor maternal vascular malperfusion, but the data in the literature remain contradictory. The objective of the study was to evaluate the association between the PAI-1 4G/5G, MTHFR C677T and factor V Leiden G1691A polymorphisms and fetal growth restriction, as well as to analyze the dose–effect relationship between the number of thrombophilic variants and the severity of restriction. Methods: This was a retrospective case–control study including 480 singleton pregnancies: 240 cases with fetal growth restriction and 240 pregnant women with eutrophic fetuses, followed up for a period of five years. Cases were defined biometrically as an estimated fetal weight below the 10th centile, without Doppler confirmation, and the phenotype therefore corresponds to small-for-gestational-age rather than to the full consensus definition of fetal growth restriction; a secondary analysis restricted to cases below the 5th centile, performed in response to review, is reported. Maternal characteristics, genotypes, perinatal outcomes, and cumulative pattern of thrombophilic variants were analyzed. Results: PAI-1 4G allele carriers were significantly more frequent in the growth restriction group compared to the control group (70.8% vs. 44.6%; OR 3.02; 95% CI 2.07–4.40; p < 0.001), as were MTHFR C677T allele carriers (57.1% vs. 39.2%; OR 2.07; 95% CI 1.44–2.97; p < 0.001) and factor V Leiden carriers (33.3% vs. 12.1%; OR 3.64; 95% CI 2.27–5.83; p < 0.001). Carrier prevalence increased progressively with severity of restriction for the PAI-1 4G allele and, most steeply, for factor V Leiden (from 12.1% in controls to 75.0% below the 3rd centile; trend test p < 0.001); for the MTHFR 677T allele the increase was confined in the two case strata above the 3rd centile, and the estimate in the smallest subgroup was uninformative. The risk of growth restriction increased with the number of coexisting thrombophilic variants: OR 2.12 (95% CI 1.24–3.64) for one variant, OR 5.60 (95% CI 3.21–9.78) for two, and OR 24.42 (95% CI 7.87–75.78) for all three, compared with the absence of any variant. In multivariable analysis, the three polymorphisms remained independent predictors, with the strongest adjusted association being that of factor V Leiden (adjusted OR 3.33; 95% CI 2.03–5.47). Carriage of each variant was associated with a lower birth-weight centile: −12.3 points for PAI-1 4G, −10.2 for factor V Leiden and −8.0 for MTHFR C677T (all p < 0.001). Conclusions: In this study, PAI-1 4G/5G, MTHFR C677T, and factor V Leiden polymorphisms were independently associated with fetal growth restriction. The results are compatible with a contribution of hypofibrinolysis and inherited thrombophilia to the placental insufficiency phenotype, most clearly in the more severe strata, but they are associative and require confirmation in prospective cohorts incorporating Doppler assessment and placental histopathology.

  • Open Access

    Uridine Improves Locomotor Activity and Sciatic Nerve Integrity in a Mouse Model of Diabetes Mellitus

    by Anca-Maria Țucă, Smaranda Ioana Mitran, Emilia Burada, Alexandra Nicoleta Preda, Alexandra Oltea Dan, Elena-Anca Târtea, Andrei GreșIță, Răzvan-Cosmin Pană, Diana-Ruxandra Hădăreanu, Veronica Sfredel, et al.

    Diabetic peripheral neuropathy is an important cause of functional disability, and current therapies have limited ability to halt its progression. Uridine, a pyrimidine nucleoside essential for the synthesis of membrane phospholipids and neuronal metabolism, appears to be a potential neuroprotective agent, but its impact on motor behavior and peripheral nerve integrity in diabetes remains insufficiently investigated. Our study investigated the effects of chronic uridine supplementation on locomotor performance, neuromuscular electrophysiological manifestations, and morphological changes in the sciatic nerve in a murine model of streptozotocin-induced diabetes. We used male C57BL/6 mice (n = 8/group) that were assigned to three groups: sham (no diabetes), diabetic (streptozotocin-induced, diabetes mellitus, DM+), and diabetic treated with uridine (DM+U). We observed that uridine did not alter the metabolic status, as the HbA1c values remained comparable between diabetic groups (9.93 ± 0.57% DM+ vs. 9.71 ± 0.55% DM+U; p = 0.72), suggesting effects independent of glycemic control. The open field test revealed that diabetic mice showed a marked reduction in spontaneous locomotion, while uridine-treated mice maintained a significantly higher level of activity (longer total distance traveled 3761.7 ± 789.1 cm vs. 2477.5 ± 1017.6 cm in DM+; p = 0.023). Electrophysiological evaluation revealed near-normal sciatic nerve function in DM+U mice, including higher compound motor action potential (CMAP) amplitudes (10.21 ± 0.64 mV vs. 5.75 ± 0.72 mV; p < 0.0001) and reduced F-wave latency (6.35 ± 0.45 ms vs. 7.29 ± 0.31 ms; p < 0.0001). Histological and immunohistochemical analyses (PGP 9.5) further confirmed reduced nerve degeneration in DM+U mice. Our data suggest that chronic uridine administration may confer both functional and structural neuroprotection in diabetic neuropathy, even in the absence of improved glycemic control.

  • Open Access

    Modern Upper-Limb Rehabilitation Interventions in Stroke Patients with Spasticity

    by Ana Maria Bumbea, Rodica Trăistaru, Elena-Anca Târtea, Alexandra Oltea Dan, Adina Turcu-Stiolica, Daniela Matei, Simona Pătru, Bogdan Stefan Bumbea, Cristiana Octaviana Daia

    Background: Upper-limb rehabilitation is a decisive factor in improving the quality of life for patients who have experienced a stroke. Modern rehabilitation techniques promote the recovery of upper-limb functionality and prehension, contributing to a reduction in disability. Materials and Methods: This retrospective observational study aimed to highlight improvements in prehension through the application of current actual and modern rehabilitation techniques targeting key muscle groups involved in upper-limb recovery. Data from a total of 52 patients were identified and categorized into two groups based on the specific rehabilitation protocols they received during their hospitalization: a study group and a control group. Both groups underwent individualized rehabilitation, differing only in the type of electrotherapy applied: the study group received functional electrical stimulation (FES) and shock wave therapy (RSWT), while the control group received conventional electrical stimulation. Results: After adjusting for baseline differences in severity and time since stroke, patients in the study group demonstrated a significantly greater improvement in functional parameters compared to the control group. The results show us a significant improvement of functionality after RSWT and FES in the study group, with values from 0.28 ± 0.28 to 0.99 ± 0.36 (p-value < 0.001) regarding Hand Grip, suggesting that the treatment effect persists even when initial clinical advantages in the control group are accounted for. Muscle force increased from 0.39 ± 0.54 to 7.67 ± 3.89, p-value < 0.001. Conclusions: The combined application of functional electrical stimulation and shock wave therapy, as modern rehabilitation interventions, provided additional benefits in upper-limb and prehension rehabilitation compared to classical electrical stimulation alone. Our findings suggest that the combined application of RSWT and FES is strongly associated with improved upper-limb recovery, even after adjusting for baseline clinical imbalances. While these results support the integration of these modern techniques into stroke protocols, further prospective randomized controlled trials are needed to confirm the definitive treatment advantage over conventional methods.


  • Open Access

    Dapagliflozin Preserves Peripheral Nerve Structure and Reduces Neuropathic Damage in Streptozotocin-Induced Diabetic Peripheral Neuropathy

    by Anca-Maria Țucă, Alexandra Nicoleta Preda, Georgică Târtea, Diana-Ruxandra Hădăreanu, Eugen Țieranu, Alexandra Oltea Dan, Elena-Anca Târtea, Andrei Greșiță, Denisa Floriana Vasilica Pîrșcoveanu, Veronica Sfredel, et al.

    Diabetic peripheral neuropathy (DPN) is one of the most common chronic complications of diabetes mellitus, driven by oxidative stress, inflammation, and microvascular dysfunction. Dapagliflozin, a selective inhibitor of sodium–glucose cotransporter type 2 (SGLT2), is used in the treatment of type 2 diabetes and has pleiotropic antioxidant and anti-inflammatory effects. The aim of this study was to evaluate the neuroprotective effects of dapagliflozin in an experimental model of streptozotocin (STZ)-induced diabetic peripheral neuropathy in mice. C57BL/6 mice were divided into three groups: control (DM–), STZ-induced diabetes (DM+), and diabetes + dapagliflozin (DM + DAPA, 10 mg/kg/day, oral administration for 12 weeks). Clinical (glycemia, weight, diuresis), electrophysiological, and histopathological parameters were evaluated, and behavioral tests (Open Field, Von Frey, Hot Tail) were performed. Dapagliflozin significantly reduced hyperglycemia, limited weight loss and polyuria, and improved locomotor behavior and nociceptive sensitivity. Electrodiagnostically, the treatment increased the amplitude and reduced the duration of motor potentials, indicating improved nerve conduction. Histological analyses showed decreased hydroxynonenal (HNE) immunoreactivity, suggesting attenuation of oxidative stress, reduced perineural fibrogenesis, and maintained intraepidermal nerve fiber density. Dapagliflozin exerts significant neuroprotective effects in experimental diabetic peripheral neuropathy by reducing oxidative stress, inflammation, and fibrosis and maintaining the structural and functional integrity of peripheral nerves.


  • Open Access

    Chitosan Protects Peripheral Nerves Against Damage Induced by Diabetes Mellitus

    by Anca-Maria Țucă, Carmen Albu, Alexandra Nicoleta Preda, Alexandra Oltea Dan, Elena-Anca Târtea, Andrei Greșiță, Denisa Floriana Vasilica Pîrșcoveanu, Veronica Sfredel, Smaranda Ioana Mitran, Georgică Târtea

    Background: Diabetic peripheral neuropathy (DPN) is one of the most common and debilitating complications of diabetes mellitus, for which current therapies do not prevent nerve degeneration. Chitosan, a biocompatible polysaccharide with antioxidant, anti-inflammatory, and lipid-lowering properties, may exert direct neuroprotective effects. This study evaluated the impact of oral administration of chitosan on peripheral nerve function and structure in a murine model of streptozotocin (STZ)-induced diabetes. Methods: Male C57BL/6 mice were divided into three groups: Sham, untreated diabetics (T1DM) and diabetics treated with chitosan (150 mg/kg/day, 12 weeks). Metabolic, behavioral (Open Field), nociceptive (Von Frey, Tail-Flick), electrophysiological (compound motor action potential—CMAP) and histological (intraepidermal nerve fiber density—IENF) parameters were analyzed. Results: Chitosan did not significantly modify blood glucose (p = 0.3366), but showed favorable metabolic effects, reducing LDL cholesterol in T1DM+Chitosan vs. T1DM mice (43.75 ± 5.62 mg/dL vs. 82.75 ± 7.65 mg/dL, p < 0.0001) as well as triglycerides (103.5 ± 12.8 mg/dL vs. 175.5 ± 22.8 mg/dL, p < 0.0001). In nociceptive tests, chitosan ameliorated thermal hyperalgesia (Tail-Flick: T1DM 1.25 ± 0.19 s vs. T1DM+Chitosan 1.54 ± 0.16 s; p = 0.0188) and mechanical allodynia (Von Frey: T1DM 0.16 ± 0.07 g vs. T1DM+Chitosan 0.38 ± 0.15 g, p = 0.0103). Electrodiagnostically, chitosan improved CMAP amplitude (T1DM 5.756 ± 0.706 mV vs. T1DM + Chitosan 6.756 ± 0.760 mV, p = 0.0409) and reduced CMAP duration (3.161 ± 0.217 ms vs. 2.900 ± 0.080 ms, p = 0.0273). Histologically, IENF density significantly increased in the treated group (0.01991 ± 0.00246 vs. 0.01512 ± 0.00253 in T1DM; p = 0.0200). Conclusions: Oral administration of chitosan confers functional and structural neuroprotection in STZ-induced diabetic neuropathy despite persistent hyperglycemia.